|
| | Publication Year | Title | Author(s) |
| 1 | Feb-2022 | Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. | Goldinger, Simone M; Buder-Bakhaya, Kristina; Lo, Serigne N; Forschner, Andrea; McKean, Meredith; Zimmer, Lisa; Khoo, Chloe; Dummer, Reinhard; Eroglu, Zeynep; Buchbinder, Elizabeth I; Ascierto, Paolo A; Gutzmer, Ralf; Rozeman, Elisa A; Hoeller, Christoph; Johnson, Douglas B; Gesierich, Anja; Kölblinger, Peter; Bennannoune, Naima; Cohen, Justine V; Kähler, Katharina C; Wilson, Melissa A; Cebon, Jonathan S ; Atkinson, Victoria; Smith, Jessica L; Michielin, Olivier; Long, Georgina V; Hassel, Jessica C; Weide, Benjamin; Haydu, Lauren E; Schadendorf, Dirk; McArthur, Grant; Ott, Patrick A; Blank, Christian; Robert, Caroline; Sullivan, Ryan; Hauschild, Axel; Carlino, Matteo S; Garbe, Claus; Davies, Michael A; Menzies, Alexander M |
| 2 | 12-Nov-2018 | Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. | Mitchell, Emma L; Lau, Peter Kar Han; Khoo, Chloe; Liew, David F; Leung, Jessica; Liu, Bonnia ; Rischin, Adam; Frauman, Albert G ; Kee, Damien ; Smith, Kortnye; Brady, Benjamin; Rischin, Danny; Gibson, Andrew; Mileshkin, Linda; Klein, Oliver ; Weickhardt, Andrew; Arulananda, Surein; Shackleton, Mark; McArthur, Grant; Östör, Andrew; Cebon, Jonathan S ; Solomon, Benjamin; Buchanan, Russell R C ; Wicks, Ian P; Lo, Serigne; Hicks, Rodney J; Sandhu, Shahneen |
| 3 | 2018 | Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of IntralesionalBacillus Calmette-Guérinfollowed by Ipilimumab in Patients with Advanced Metastatic Melanoma. | Da Gama Duarte, Jessica; Parakh, Sagun ; Andrews, Miles C; Woods, Katherine; Pasam, Anupama; Tutuka, Candani; Ostrouska, Simone; Blackburn, Jonathan M; Behren, Andreas; Cebon, Jonathan S |
| 4 | 7-Sep-2017 | Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. | Ribas, Antoni; Dummer, Reinhard; Puzanov, Igor; VanderWalde, Ari; Andtbacka, Robert H I; Michielin, Olivier; Olszanski, Anthony J; Malvehy, Josep; Cebon, Jonathan S ; Fernandez, Eugenio; Kirkwood, John M; Gajewski, Thomas F; Chen, Lisa; Gorski, Kevin S; Anderson, Abraham A; Diede, Scott J; Lassman, Michael E; Gansert, Jennifer; Hodi, F Stephen; Long, Georgina V |
| 5 | 28-Jun-2017 | PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. | Tutuka, Candani S A; Andrews, Miles C; Mariadason, John M ; Ioannidis, Paul; Hudson, Christopher; Cebon, Jonathan S ; Behren, Andreas |
| 6 | Dec-2016 | Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. | Atkinson, Victoria; Long, Georgina V; Menzies, Alexander M; McArthur, Grant; Carlino, Matteo S; Millward, Michael; Roberts-Thomson, Rachel; Brady, Benjamin; Kefford, Richard; Haydon, Andrew; Cebon, Jonathan S |
| 7 | 16-Nov-2016 | Systems analysis identifies miR-29b regulation of invasiveness in melanoma | Andrews, Miles C; Cursons, Joseph; Hurley, Daniel G; Anaka, Matthew; Cebon, Jonathan S ; Behren, Andreas; Crampin, Edmund J |
| 8 | Jul-2016 | Identifying and targeting determinants of melanoma cellular invasion | Jayachandran, Aparna; Prithviraj, Prashanth; Lo, Pu-Han; Walkiewicz, Marzena; Anaka, Matthew; Woods, Briannyn; Behren, Andreas; Cebon, Jonathan S ; McKeown, SJ |
| 9 | 10-Mar-2016 | Overall survival and durable responses in patients with BRAF V600–mutant metastatic melanoma receiving dabrafenib combined with trametinib | Long, Georgina V; Weber, Jeffrey s; Infante, Jeffrey R; Kim, Kevin B; Daud, Adil; Gonzalez, Rene; Sosman, Jeffrey A; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan S ; Kefford, Richard F; Lawrence, Donald P; Kudchadkar, Ragini; Burris, Howard A; Falchook, Gerald S; Algazi, Alain; Lewis, Karl; Puzanov, Igor; Ibrahim, Nageatte; Sun, Peng; Cunningham, Elizabeth; Kline, Amy S; Del Buono, Heather; McDowell, Diane Opatt; Patel, Kiran; Flaherty, Keith T |
| 10 | 16-Feb-2016 | Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma | Woods, K; Knights, AJ; Anaka, M; Schittenhelm, RB; Purcell, AW; Behren, Andreas; Cebon, Jonathan S |
| 11 | 1-Dec-2015 | Cellular mechanisms underlying complete hematological response of chronic myeloid leukemia to BRAF and MEK1/2 inhibition in a patient with concomitant metastatic melanoma | Andrews, Miles C; Turner, Natalie; Boyd, Janis; Roberts, Andrew W; Grigg, Andrew P ; Behren, Andreas; Cebon, Jonathan S |
| 12 | Dec-2015 | Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes | Wilmott, James S; Field, Matthew A; Johansson, Peter A; Kakavand, Hojabr; Shang, Ping; De Paoli-Iseppi, Ricardo; Vilain, Ricardo E; Pupo, Gulietta M; Tembe, Varsha; Jakrot, Valerie; Shang, Catherine A; Cebon, Jonathan S ; Shackleton, Mark; Fitzgerald, Anna; Thompson, John F; Hayward, Nicholas K; Mann, Graham J; Scolyer, Richard A |
| 13 | 10-Apr-2015 | Pregnancy Associated Plasma Protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion. | Prithviraj, Prashanth; Anaka, Matthew; McKeown, Sonja J; Permezel, Michael; Walkiewicz, Marzena; Cebon, Jonathan S ; Behren, Andreas; Jayachandran, Aparna |
| 14 | 17-Dec-2014 | Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells. | Woods, Katherine; Pasam, Anupama; Jayachandran, Aparna; Andrews, Miles C; Cebon, Jonathan S |
| 15 | 1-Jun-2014 | Evolving role of tumor antigens for future melanoma therapies. | Andrews, Miles C; Woods, Katherine; Cebon, Jonathan S ; Behren, Andreas |
Loading...
2
0
20
0
false
0000-0002-3898-950x